Kannan Raman
Kannan Raman has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Gowramma Byran
Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India
3 shared publications - Kalirajan Rajagopal
Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India
3 shared publications - Talha Bin Emran
Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh
3 shared publications - Ashok Kumar Janakiraman
Faculty of Pharmaceutical Sciences, UCSI University, 56000 Cheras, Kuala Lumpur, Malaysia
2 shared publications - Baliwada Aparna
Department of Pharmaceutical Chemistry Malla Reddy Pharmacy College Hyderabad India
2 shared publications - Dhani Ramachandran
Management & Science University
2 shared publications
Latest Publications
- RetractedOpen Access
- 8 November 2024
- Published by EDP Sciences in E3S Web of Conferences
- Vol. 588, 01018
RETRACTED: Nano-Innovations for a Greener Future: Exploring the Intersection of Nanotechnology and Environmental Sustainability
We take a zero tolerance to any situation where fraudulent research is published in our journals. As a result, this article has been retracted by the Publisher because it is suspected to be a nonsensical computer-generated publication with a number of tortured phrases and irrelevant references. Additional measures have been implemented to prevent these issues from reoccurring. EDP Sciences is extremely grateful to anonymous whistleblowers and the Problematic Paper Screener for bringing this case to our attention for further investigations.
- 8 November 2024
- Published by EDP Sciences in E3S Web of Conferences
- Vol. 588, 01018
RetractedOpen AccessRETRACTED: Nano-Innovations for a Greener Future: Exploring the Intersection of Nanotechnology and Environmental Sustainability
We take a zero tolerance to any situation where fraudulent research is published in our journals. As a result, this article has been retracted by the Publisher because it is suspected to be a nonsensical computer-generated publication with a number of tortured phrases and irrelevant references. Additional measures have been implemented to prevent these issues from reoccurring. EDP Sciences is extremely grateful to anonymous whistleblowers and the Problematic Paper Screener for bringing this case to our attention for further investigations.
- 24 October 2024
- Published by Springer Nature
- p. 475-509
Biomarkers of Alzheimer’s Disease
- 20 June 2024
- Published by Springer Nature
- p. 1-35
Biomarkers of Alzheimer’s Disease
- RetractionOpen Access
- 1 January 2024
- Published by EDP Sciences in E3S Web of Conferences
- Vol. 588, 01021
Retraction Notice: Nano-Innovations for a Greener Future: Exploring the Intersection of Nanotechnology and Environmental Sustainability
We take a zero tolerance to any situation where fraudulent research is published in our journals. As a result, this article has been retracted by the Publisher because it is suspected to be a nonsensical computer-generated publication with a number of tortured phrases and irrelevant references. Additional measures have been implemented to prevent these issues from reoccurring. EDP Sciences is extremely grateful to anonymous whistleblowers and the Problematic Paper Screener for bringing this case to our attention for further investigations.
- 1 January 2024
- Published by EDP Sciences in E3S Web of Conferences
- Vol. 588, 01021
RetractionOpen AccessRetraction Notice: Nano-Innovations for a Greener Future: Exploring the Intersection of Nanotechnology and Environmental Sustainability
We take a zero tolerance to any situation where fraudulent research is published in our journals. As a result, this article has been retracted by the Publisher because it is suspected to be a nonsensical computer-generated publication with a number of tortured phrases and irrelevant references. Additional measures have been implemented to prevent these issues from reoccurring. EDP Sciences is extremely grateful to anonymous whistleblowers and the Problematic Paper Screener for bringing this case to our attention for further investigations.
- Open Access
- 19 April 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (6) , 2731-2742
Drug target of natural products and COVID-19: how far has science progressed?
The new coronavirus [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] that caused a viral disease with a high risk of mortality (coronavirus disease 2019) was found toward the end of 2019. This was a significant acute respiratory syndrome. In a brief period, this virus spread throughout the entire planet, causing tremendous loss of life and economic damage. The process of developing new treatments takes time, and there are presently no recognized specific treatments to treat this infection. The most promising participants, who subsequently developed into prospective leads, were dropped from the clinical research in their latter phases. Medication that has previously acquired permission may only be repurposed for use for various medical reasons following a thorough investigation for safety and effectiveness. Because there are now no effective treatments available, natural products are being used haphazardly as antiviral medications and immunity boosters. The fundamental statement that most natural compounds have powerful antiviral action does not apply to SARS-CoV-2. Middle East respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus infections are inhibited by natural treatments. According to an in silico study, the virus’ nonstructural proteins, including PLpro, Mpro, and RdRp, as well as structural proteins like the spike (S) protein, have been shown to have a strong affinity for several natural products and to be inhibited by them. The virus also suggests that it is a valid candidate for therapeutic research since it utilizes the intracellular angiotensin-converting enzyme 2 receptor of the host cell. In this study, interesting targets for SARS-CoV-2 medication development are explored, as well as the antiviral properties of some well-known natural compounds.
- 19 April 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (6) , 2731-2742
Open AccessDrug target of natural products and COVID-19: how far has science progressed?
The new coronavirus [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] that caused a viral disease with a high risk of mortality (coronavirus disease 2019) was found toward the end of 2019. This was a significant acute respiratory syndrome. In a brief period, this virus spread throughout the entire planet, causing tremendous loss of life and economic damage. The process of developing new treatments takes time, and there are presently no recognized specific treatments to treat this infection. The most promising participants, who subsequently developed into prospective leads, were dropped from the clinical research in their latter phases. Medication that has previously acquired permission may only be repurposed for use for various medical reasons following a thorough investigation for safety and effectiveness. Because there are now no effective treatments available, natural products are being used haphazardly as antiviral medications and immunity boosters. The fundamental statement that most natural compounds have powerful antiviral action does not apply to SARS-CoV-2. Middle East respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus infections are inhibited by natural treatments. According to an in silico study, the virus’ nonstructural proteins, including PLpro, Mpro, and RdRp, as well as structural proteins like the spike (S) protein, have been shown to have a strong affinity for several natural products and to be inhibited by them. The virus also suggests that it is a valid candidate for therapeutic research since it utilizes the intracellular angiotensin-converting enzyme 2 receptor of the host cell. In this study, interesting targets for SARS-CoV-2 medication development are explored, as well as the antiviral properties of some well-known natural compounds.
- Open Access
Acridine as an Anti-Tumour Agent: A Critical Review
This review summarized the current breakthroughs in the chemistry of acridines as anti-cancer agents, including new structural and biologically active acridine attributes. Acridine derivatives are a class of compounds that are being extensively researched as potential anti-cancer drugs. Acridines are well-known for their high cytotoxic activity; however, their clinical application is restricted or even excluded as a result of side effects. The photocytotoxicity of propyl acridine acts against leukaemia cell lines, with C1748 being a promising anti-tumour drug against UDP-UGT’s. CK0403 is reported in breast cancer treatment and is more potent than CK0402 against estrogen receptor-negative HER2. Acridine platinum (Pt) complexes have shown specificity on the evaluated DNA sequences; 9-anilinoacridine core, which intercalates DNA, and a methyl triazene DNA-methylating moiety were also studied. Acridine thiourea gold and acridinone derivatives act against cell lines such as MDA-MB-231, SK-BR-3, and MCF-7. Benzimidazole acridine compounds demonstrated cytotoxic activity against Dual Topo and PARP-1. Quinacrine, thiazacridine, and azacridine are reported as anti-cancer agents, which have been reported in the previous decade and were addressed in this review article.
Open AccessAcridine as an Anti-Tumour Agent: A Critical Review
This review summarized the current breakthroughs in the chemistry of acridines as anti-cancer agents, including new structural and biologically active acridine attributes. Acridine derivatives are a class of compounds that are being extensively researched as potential anti-cancer drugs. Acridines are well-known for their high cytotoxic activity; however, their clinical application is restricted or even excluded as a result of side effects. The photocytotoxicity of propyl acridine acts against leukaemia cell lines, with C1748 being a promising anti-tumour drug against UDP-UGT’s. CK0403 is reported in breast cancer treatment and is more potent than CK0402 against estrogen receptor-negative HER2. Acridine platinum (Pt) complexes have shown specificity on the evaluated DNA sequences; 9-anilinoacridine core, which intercalates DNA, and a methyl triazene DNA-methylating moiety were also studied. Acridine thiourea gold and acridinone derivatives act against cell lines such as MDA-MB-231, SK-BR-3, and MCF-7. Benzimidazole acridine compounds demonstrated cytotoxic activity against Dual Topo and PARP-1. Quinacrine, thiazacridine, and azacridine are reported as anti-cancer agents, which have been reported in the previous decade and were addressed in this review article.
- Open Access
- 2 July 2022
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 80, 104062
Role of natural products towards the SARS-CoV-2: A critical review
Despite the fact that various therapeutic compounds are being investigated, there is still a scarcity of effective and reliable therapeutic regimens to treat COVID-19. Ever since the COVID-19 pandemic, a diversity of traditional herbal treatments has been investigated to cure infected people, either alone or in conjunction with mainstream pharmaceuticals, with encouraging outcomes. In this article, we look at the latest research on the usage of natural products to alleviate the severity of COVID-19. To determine the activity of the natural products, act against SARS-CoV-2 to various targets like Mpro, ACE-II, papain-like, chymotrypsin-like proteases, and some antiviral targets. The processes underlying this preventative or therapeutic action are also examined. We used PubMed, Scopus, Google Scholar, and the WHO site to perform our review. The anti-SARS-CoV-2 impacts of various herbal extracts and purified compounds may be mediated via direct prevention of viral replication or entrance. Interestingly, certain items might avert SARS-CoV-2 from infecting human cells by blocking the ACE-2 protein or the serine protease TMPRRS2. Natural products have also been stated to suppress proteins intricate in the virus life cycle, like papain-like and chymotrypsin-like proteases. To conclude, natural products can be used alone or in combination as remedies or treatments for COVID-19. In addition, their compositions may provide insight into the development of effective and reliable antiviral drugs.
- 2 July 2022
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 80, 104062
Open AccessRole of natural products towards the SARS-CoV-2: A critical review
Despite the fact that various therapeutic compounds are being investigated, there is still a scarcity of effective and reliable therapeutic regimens to treat COVID-19. Ever since the COVID-19 pandemic, a diversity of traditional herbal treatments has been investigated to cure infected people, either alone or in conjunction with mainstream pharmaceuticals, with encouraging outcomes. In this article, we look at the latest research on the usage of natural products to alleviate the severity of COVID-19. To determine the activity of the natural products, act against SARS-CoV-2 to various targets like Mpro, ACE-II, papain-like, chymotrypsin-like proteases, and some antiviral targets. The processes underlying this preventative or therapeutic action are also examined. We used PubMed, Scopus, Google Scholar, and the WHO site to perform our review. The anti-SARS-CoV-2 impacts of various herbal extracts and purified compounds may be mediated via direct prevention of viral replication or entrance. Interestingly, certain items might avert SARS-CoV-2 from infecting human cells by blocking the ACE-2 protein or the serine protease TMPRRS2. Natural products have also been stated to suppress proteins intricate in the virus life cycle, like papain-like and chymotrypsin-like proteases. To conclude, natural products can be used alone or in combination as remedies or treatments for COVID-19. In addition, their compositions may provide insight into the development of effective and reliable antiviral drugs.